Skip to content
All Podcasts – Lifestyle
Author:
Climb Bio, Inc.
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
April 7, 2026
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 6, 2026
←
Previous Page
1
2